Insider Transactions in Q1 2025 at Ani Pharmaceuticals Inc (ANIP)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 13
2025
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
400
-0.49%
|
$25,200
$63.33 P/Share
|
|
Mar 07
2025
|
Ori Gutwerg SVP, GENERICS |
SELL
Payment of exercise price or tax liability
|
Direct |
3,314
-3.52%
|
$198,840
$60.62 P/Share
|
|
Mar 07
2025
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
17,060
-3.39%
|
$1,023,600
$60.62 P/Share
|
|
Mar 07
2025
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Payment of exercise price or tax liability
|
Direct |
2,874
-2.52%
|
$172,440
$60.62 P/Share
|
|
Mar 07
2025
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,150
-2.68%
|
$309,000
$60.62 P/Share
|
|
Mar 07
2025
|
Krista Davis SVP, CHIEF HR OFFICER |
SELL
Open market or private sale
|
Direct |
1,000
-1.48%
|
$60,000
$60.86 P/Share
|
|
Mar 05
2025
|
Ori Gutwerg SVP, GENERICS |
SELL
Open market or private sale
|
Direct |
5,384
-2.71%
|
$323,040
$60.01 P/Share
|
|
Mar 05
2025
|
Ori Gutwerg SVP, GENERICS |
BUY
Exercise of conversion of derivative security
|
Direct |
300
+0.3%
|
$9,300
$31.49 P/Share
|
|
Feb 28
2025
|
Thomas Andrew Rowland SVP, HEAD - ESTABLISHED BRANDS |
SELL
Payment of exercise price or tax liability
|
Direct |
627
-1.36%
|
$38,247
$61.89 P/Share
|
|
Feb 28
2025
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
12,216
-2.37%
|
$745,176
$61.89 P/Share
|
|
Feb 28
2025
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Payment of exercise price or tax liability
|
Direct |
1,275
-1.1%
|
$77,775
$61.89 P/Share
|
|
Feb 28
2025
|
Krista Davis SVP, CHIEF HR OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,099
-1.6%
|
$67,039
$61.89 P/Share
|
|
Feb 28
2025
|
Ori Gutwerg SVP, GENERICS |
SELL
Payment of exercise price or tax liability
|
Direct |
1,570
-1.56%
|
$95,770
$61.89 P/Share
|
|
Feb 28
2025
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,861
-0.96%
|
$113,521
$61.89 P/Share
|
|
Feb 28
2025
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,099
-1.34%
|
$67,039
$61.89 P/Share
|
|
Feb 21
2025
|
Krista Davis SVP, CHIEF HR OFFICER |
SELL
Open market or private sale
|
Direct |
1,000
-1.44%
|
$60,000
$60.2 P/Share
|
|
Feb 15
2025
|
Ori Gutwerg SVP, GENERICS |
SELL
Payment of exercise price or tax liability
|
Direct |
1,167
-1.15%
|
$67,686
$58.92 P/Share
|
|
Feb 15
2025
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Payment of exercise price or tax liability
|
Direct |
1,184
-1.02%
|
$68,672
$58.92 P/Share
|
|
Feb 14
2025
|
Ori Gutwerg SVP, GENERICS |
SELL
Payment of exercise price or tax liability
|
Direct |
1,426
-1.38%
|
$82,708
$58.92 P/Share
|
|
Feb 14
2025
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,799
-1.49%
|
$452,342
$58.92 P/Share
|
|
Feb 14
2025
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Payment of exercise price or tax liability
|
Direct |
1,473
-1.25%
|
$85,434
$58.92 P/Share
|
|
Feb 14
2025
|
Thomas Andrew Rowland SVP, HEAD - ESTABLISHED BRANDS |
SELL
Payment of exercise price or tax liability
|
Direct |
582
-1.25%
|
$33,756
$58.92 P/Share
|
|
Feb 14
2025
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,730
-0.88%
|
$100,340
$58.92 P/Share
|
|
Feb 14
2025
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,434
-1.72%
|
$83,172
$58.92 P/Share
|
|
Feb 14
2025
|
Krista Davis SVP, CHIEF HR OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,196
-1.69%
|
$69,368
$58.92 P/Share
|
|
Feb 13
2025
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
400
-0.48%
|
$23,600
$59.54 P/Share
|
|
Feb 12
2025
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
BUY
Grant, award, or other acquisition
|
Direct |
23,936
+12.06%
|
-
|
|
Feb 12
2025
|
Ori Gutwerg SVP, GENERICS |
BUY
Grant, award, or other acquisition
|
Direct |
26,112
+11.81%
|
-
|
|
Feb 12
2025
|
Nikhil Lalwani PRESIDENT & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
152,331
+13.48%
|
-
|
|
Feb 12
2025
|
Christopher Mutz HEAD OF RARE DISEASE |
BUY
Grant, award, or other acquisition
|
Direct |
41,346
+15.95%
|
-
|
|
Feb 12
2025
|
Thomas Andrew Rowland SVP, HEAD - ESTABLISHED BRANDS |
BUY
Grant, award, or other acquisition
|
Direct |
13,056
+12.98%
|
-
|
|
Feb 12
2025
|
Stephen P. Carey SVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
41,346
+9.97%
|
-
|
|
Feb 12
2025
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
BUY
Grant, award, or other acquisition
|
Direct |
28,290
+15.42%
|
-
|
|
Feb 12
2025
|
Krista Davis SVP, CHIEF HR OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
21,761
+14.16%
|
-
|
|
Feb 12
2025
|
Chad Gassert SVP - CORP. DEV. & STRATEGY |
BUY
Grant, award, or other acquisition
|
Direct |
23,936
+14.91%
|
-
|
|
Jan 13
2025
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
400
-0.71%
|
$21,200
$53.92 P/Share
|